Introduction -Dameshek's riddle
In an editorial to Blood in 1967, William Dameshek 1 offered his now famous riddle: what do aplastic anemia, paroxysmal nocturnal hemoglobinuria and 'hypoplastic' leukemia have in common? Dameshek and others before him noticed that paroxysmal nocturnal hemoglobinuria (PNH) and secondary myelodysplastic syndrome (MDS)/acute leukemia not infrequently evolve from severe aplastic anemia (SAA). Since 1967, much has been learned about these diseases. It is now clear that the bone marrow failure in most cases of SAA results from an autoimmune attack mediated by cytotoxic T cells. 2 PNH has been shown to be a clonal expansion of hematopoietic stem cells that possess somatic mutations in an X-linked gene termed PIG-A. 3 PIG-A mutations lead to a deficiency or absence of glycosylphosphatidylinositol-anchored proteins. MDS is also a clonal hematopoietic stem cell disorder that is frequently associated with heterogeneous karyotypic abnormalities often involving chromosomes 5, 7, or 8. Although our understanding of the pathophysiology and the ability to diagnose these disorders has improved, it remains unclear how these seemingly distinct diseases are linked.
Before the introduction of effective immunosuppressive therapy with antilymphocyte/antithymocyte globulin and cyclosporine for the treatment of SAA, most patients died of their disease within a year of diagnosis. In addition, probably because of their short survival, SAA patients rarely developed secondary clonal disorders. With improvement in survival as a result of immunosuppressive therapy, 10-30% of SAA patients ultimately develop MDS or PNH. [4] [5] [6] Interestingly, allogeneic transplantation essentially eliminates this risk. 7 Secondary clonal disorders following noncytotoxic therapy for leukemia Classical therapy-related MDS/acute leukemia (tMDS) follows the use of alkylating agents such as cyclophosphamide, or topoisomerase II inhibitors such as anthracyclines and the epipodophillotoxins. In these cases, tMDS appears to be a direct result of the cytotoxic anticancer agents. However, clonal cytogenetic abnormalities, possibly representing MDS, have now been reported in two settings following noncytotoxic therapy that targets the respective disease: all trans retinoic acid (ATRA) in acute promyelocytic leukemia (APL) and imatinib in chronic myeloid leukemia (CML).
APL is a subtype of acute myeloid leukemia associated with a specific chromosomal translocation t(15;17) that results in the fusion of the promyelocytic leukemia (PML) and retinoic acid receptor a (RARa) genes. Standard cytarabine-anthracyclinebased chemotherapy cured 20-30% of patients with virtually no risk of tMDS. 8 In the early 1990s, APL was found to be responsive both in vivo and in vitro to ATRA; its front-line use combined with standard antileukemic chemotherapy raised the cure rate of APL to greater than 60%. 8 However, long-term follow-up of these patients revealed an increased risk for the development of MDS (1-7%) in the non-APL cells.
9,10 Although many of the APL patients developing MDS after ATRA in one study also had received alkylating agents, 9 this has not been the case in most of the reports. 10 Moreover, ATRA-treated APL patients generally receive less total chemotherapy than those previously treated just with standard antileukemic chemotherapy.
The cytogenetic hallmark of CML, the Philadelphia chromosome (Ph), is a reciprocal translocation, t(9;22)(q34;q11), involving the transfer of c-abl sequences from chromosome 9 to a site adjacent to the BCR sequences on chromosome 22. 11, 12 This translocation produces a 210 kDa BCR-ABL fusion protein (p210) that is a constitutively active tyrosine kinase. 13 Recently, imatinib, a potent and relatively selective inhibitor of Abl tyrosine kinases, 14 including BCR-ABL, 15 has displayed striking clinical activity against CML. The results of the multicenter randomized trial comparing imatinib to interferon þ cytarabine 16 recently led to rapid FDA-approval of imatinib as first-line therapy, and many now consider its use as standard-ofcare. However, there are several reports of clonal cytogenetic abnormalities, possibly representing MDS, appearing in the Ph neg blood cells that recover after imatinib treatment. [17] [18] [19] [20] Although uncommon in CML before the use of imatinib, the incidence has been reported to be as high as 15% at a median follow-up of 12 months. 17 Previous treatment with cytarabine or idarubicin appeared to be a risk factor for clonal cytogenetic abnormalities in Ph neg cells in one series, 17 but not in other reports. [18] [19] [20] Moreover, most of these cases have involved cytogenetic abnormalities (trisomy 8, abnormalities of chromosomes 5 or 7) that are associated with tMDS following alkylating agents, and cytarabine and idarubicin have not been reported to induce this type of tMDS.
'Field leukemogenic effect'
It seems unlikely that clonal cytogenetic changes are induced by the immunosuppressive therapy in aplastic anemia, ATRA in APL, or imatinib in CML. In fact, Fialkow et al 21 reported the presence of Ph neg clonal cells in CML over two decades ago. However, the secondary clonal changes that develop following the noncytotoxic therapies used in these three diseases may be indirectly related to the respective treatments. It is possible that SAA, APL, CML, MDS, and potentially other acquired bone marrow disorders represent different manifestations of generalized insults to the bone marrow. A primary insult to hematopoietic progenitor cells could lead to several abnormal cell clones; eventually one clone could dominate, with the others still present but below the level of detection. This would be analogous to the 'field cancerization effect' described in aerodigestive and other solid tumors to explain second primary tumors in the affected tissue. 22, 23 This field effect is thought to result from tissue adjacent to the primary tumor also developing genetic alterations; 23 these alterations could result from a toxic insult such as cigarette smoke on the aerodigestive track or a genetic predisposition to genetic instability as in breast cancer.
The initial clinical manifestation of a generalized genetic insult to the bone marrow may depend on the form of the insult, the type of progenitor cells that are 'hit', the number of cells that are injured, and/or the type of growth advantage that is bestowed upon the mutant cells. In SAA, a bone marrow insult may primarily trigger an autoimmune attack on the hematopoietic progenitor compartment, perhaps by exposing cryptic epitopes or through molecular mimicry. Simultaneously, other damaged hematopoietic progenitor cells may expand and ultimately result in MDS after sufficient lag time provided by the prolongation of survival afforded SAA patients by immunosuppressive therapy. Likewise, damaged hematopoietic progenitor cells with a propensity to manifest as MDS may be inconspicuous in patients presenting initially as APL or CML. Disease-specific therapy such as immunosuppressive therapy in aplastic anemia, ATRA in APL, or imatinib in CML would have no activity against other abnormal clones, allowing them to expand and become detectable as the dominant clone declines. In contrast, nonspecific cytotoxic therapies, including antileukemic chemotherapy and allogeneic BMT, have broad activity that could inhibit not only the overt disease but also other small coexistent abnormal clones.
The large numbers of both the overt diseased and normal blood cells will hamper investigating the existence of a 'field leukemogenic effect'; detecting a small abnormal clone in a background of 10 12 marrow cells could be like finding a 'needle in a haystack.' SAA may be the best disease to directly test this hypothesis. The autoimmune attack in SAA reduces the number of hematopoietic progenitor cells by 1-3 logs. 24 This may allow rare abnormal clones to be more readily detected. PNH cells, representing on average 1% of the total blood cells, can be detected in most patients with SAA at initial diagnosis using sensitive assays based on their absence of (GPI) anchors. [25] [26] [27] Since monosomy 7 is the most common chromosomal abnormality seen in MDS arising from SAA, 5, 6 sensitive techniques for detecting loss of heterozygosity (LOH) may also allow for the detection of small MDS clones that may be present in SAA at diagnosis.
Conclusion
Therapy directed against tumor-specific targets has great potential to favorably influence survival by both decreasing toxicity and enhancing disease control, as highlighted by the clinical results with ATRA in APL and imatinib in CML. However, reports of secondary clonal cytogenetic abnormalities in these two settings are concerning. Further investigation and longer follow-up are needed to establish the true incidence and significance of these findings. Nevertheless, understanding the mechanisms behind the development of these secondary clonal cytogenetic abnormalities will have profound biologic and clinical significance.
Dameshek concluded his editorial with a hypothetical answer to his riddle: 'That a single 'insult' to the marrow may be responsible for bringing about different kinds of abnormalities, sometimes occurring together, sometimes sequentially, deserves consideration, not only from the conceptual standpoint but from the experimental approach as well. ' 1 Although he did not use the terminology, Dameshek was clearly suggesting the possible existence of a 'field leukemogenic effect.' The primary insult predisposing to secondary clonal disease in primary marrow disorders could be generalized toxic damage to the bone marrow or a predisposition to genomic instability. Replicative stress to the residual normal hematopoietic progenitor compartment has been proposed as a mechanism of secondary clonal disease in SAA. 28 However, this is unlikely to be a mechanism for MDS after ATRA in APL and imatinib in CML, as it would be expected to produce secondary clonal disease in the setting of nonspecific cytotoxic therapy as well. The coexistence of small abnormal clones, in addition to the dominant disease, could limit the therapeutic effectiveness of all targeted therapies being developed for acquired bone marrow disorders. Thus, the answer to Dameshek's riddle may have more relevance today than when he proposed it nearly 40 years ago.
